Turbogen VP Dan Katz reports 37,157-share stake
Turbogen Ltd. (TRBG) disclosed the initial insider holdings of Dan Katz, Vice President of Manufacturing.
Rhea-AI Filing Summary
Turbogen Ltd. (TRBG) disclosed the initial insider holdings of Dan Katz, Vice President of Manufacturing. He beneficially owns 37,157 ordinary shares, including time‑based restricted share units that convert into ordinary shares as they vest. These holdings combine directly owned shares with several RSU grants made between 2023 and 2026.
Katz also holds multiple employee stock options to acquire additional ordinary shares, with exercise prices ranging from $1.79 to $6.18 per share and expiration dates between 2031 and 2036. None of these options have been exercised as of late August 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Katz Dan
Role
VP of Manufacturing
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share option (right to buy) F3, F2 | -- | -- | -- |
| holding | Share option (right to buy) F5, F4 | -- | -- | -- |
| holding | Share option (right to buy) F7, F6 | -- | -- | -- |
| holding | Share option (right to buy) F9, F8 | -- | -- | -- |
| holding | Share option (right to buy) F11, F10 | -- | -- | -- |
| holding | Ordinary shares F1 | -- | -- | -- |
Holdings After Transaction:
Share option (right to buy) — 54,163 contracts (Direct);
Ordinary shares — 37,157 shares (Direct)
Footnotes (11)
- F1. Represents (i) 11,333 ordinary shares, no par value per share; (ii) 2,784 restricted share units ("RSUs") granted on January 26, 2023, 81.25% of which vested and the remaining 18.75% vest in equal quarterly installments of 6.25% thereafter, of which 2,436 RSUs have vested as of August 25, 2026; (iii) 3,520 RSUs granted on December 31, 2023, 56.25% of which vested and the remaining 43.75% vest in equal quarterly installments of 6.25% thereafter, of which 1,980 RSUs have vested and 1,540 remain unvested as of August 25, 2026; (iv) 3,520 RSUs granted on March 30, 2025, which vest in equal quarterly installments of 6.25% thereafter, of which 3,520 RSUs remain unvested as of August 25, 2026; and (v) 16,000 RSUs granted on April 29, 2026, 41.6% of which and vested and the remaining 58.3% vest in equal quarterly installments of 8.33% thereafter, of which 6,666 RSUs have vested and 9,334 RSUS remain unvested as of August 25, 2026. Each RSU represents the right to receive one ordinary share.
- F2. A total of 1,000 options were granted on August 9, 2021 and vested in equal quarterly installments of 6.25% beginning July 1, 2021. As of August 25, 2026, 1,000 options are fully vested and none have been exercised into ordinary shares. Number of ordinary shares issuable upon exercise of the options reflects adjustments to the Company's issued and outstanding share capital between 2021 and 2023.
- F3. The options were granted with an exercise price of NIS 9.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026, resulting in an exercise price of $3.28 per share.
- F4. A total of 8,400 options were granted on January 26, 2023 and vested in equal quarterly installments of 6.25% beginning January 26, 2023. As of August 25, 2026, 6,876 options are fully vested and none have been exercised into ordinary shares. Number of ordinary shares issuable upon exercise of the options reflects adjustments to the Company's issued and outstanding share capital between 2021 and 2023.
- F5. The options were granted with an exercise price of NIS 10.35 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026, resulting in an exercise price of $3.45 per share.
- F6. A total of 9,776 options were granted on December 31, 2023 and vested in equal quarterly installments of 6.25% beginning December 30, 2023. As of August 25, 2026, 5,540 options are fully vested and none have been exercised into ordinary shares. Number of ordinary shares issuable upon exercise of the options reflects adjustments to the Company's issued and outstanding share capital between 2021 and 2023.
- F7. The options were granted with an exercise price of NIS 5.38 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026, resulting in an exercise price of $1.79 per share.
- F8. A total of 9,776 options were granted on March 30, 2025 and vested in equal quarterly installments of 6.25% beginning December 30, 2024. As of August 27, 2026, none of the options are fully vested and none have been exercised into ordinary shares.
- F9. The options were granted with an exercise price of NIS 10.16 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026, resulting in an exercise price of $3.39 per share.
- F10. A total of 16,000 options were granted on April 29, 2026 and vested as follows: 33.3% vested on April 1, 2026, and the remaining 66.7% vest in equal quarterly installments of approximately 8.33% of the original grant beginning July 1, 2026. As of August 25, 2026, 6,667 options are fully vested and none have been exercised into ordinary shares.
- F11. The options were granted with an exercise price of NIS 18.5 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026, resulting in an exercise price of $6.18 per share.
Key Figures
Beneficially owned ordinary shares: 37,157 shares
Directly owned ordinary shares: 11,333 shares
RSUs granted January 26, 2023: 2,784 units
+5 more
8 metrics
Beneficially owned ordinary shares
37,157 shares
Direct and RSU-based holdings as of August 25, 2026
Directly owned ordinary shares
11,333 shares
Portion of total beneficial holdings described in the equity breakdown
RSUs granted January 26, 2023
2,784 units
2,436 RSUs vested as of August 25, 2026; balance vesting quarterly
RSUs granted December 31, 2023
3,520 units
1,980 vested and 1,540 unvested as of August 25, 2026
RSUs granted April 29, 2026
16,000 units
6,666 vested and 9,334 unvested as of August 25, 2026
Option exercise price (earliest grant)
$3.28 per share
Options expiring August 9, 2031 on 10,075 underlying ordinary shares
Lowest reported option exercise price
$1.79 per share
Options on 9,849 underlying shares granted December 31, 2023
Highest reported option exercise price
$6.18 per share
Options on 16,000 underlying shares granted April 29, 2026
Key Terms
restricted share units, vested, exercise price, beneficially owns
4 terms
vested financial
"2,436 RSUs have vested as of August 25, 2026"
exercise price financial
"The options were granted with an exercise price of NIS 9.84 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
beneficially owns financial
"Represents (i) 11,333 ordinary shares, no par value per share;"
Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.
FAQ
What equity stake does Dan Katz report in Turbogen Ltd. (TRBG)?
Dan Katz reports beneficial ownership of 37,157 ordinary shares of Turbogen Ltd., consisting of directly owned ordinary shares and multiple grants of restricted share units that each represent the right to receive one ordinary share upon vesting.
How many Turbogen (TRBG) options does Dan Katz hold and at what exercise prices?
Dan Katz holds employee stock options linked to 10,075, 8,463, 9,849, 9,776 and 16,000 underlying ordinary shares, with exercise prices of $3.28, $3.45, $1.79, $3.39 and $6.18 per share, respectively.
What is the vesting status of Dan Katz’s Turbogen (TRBG) RSUs granted in 2023?
For RSUs granted January 26, 2023, 2,436 units have vested as of August 25, 2026. For RSUs granted December 31, 2023, 1,980 units have vested and 1,540 remain unvested as of that same date.
When do Dan Katz’s Turbogen (TRBG) stock options expire?
The reported option grants held by Dan Katz expire on August 9, 2031, January 26, 2033, December 31, 2033, March 30, 2035, and April 29, 2036, depending on the specific grant.
Have Dan Katz’s Turbogen (TRBG) options been exercised yet?
No. The disclosure states that as of late August 2026, no options from the reported grants have been exercised into ordinary shares; they remain outstanding employee stock options.
AI-generated analysis. How Rhea-AI works. Not financial advice.
